Shockwave Medical Inc (DELISTED) (SWAV:DL)
334.75
-0.08
(-0.02%)
USD |
NASDAQ |
May 30, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 12.57B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 21.22% |
Valuation | |
PE Ratio | 78.21 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 16.27 |
Price to Book Value | 16.72 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.9748 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 64.92% |
Profile
Shockwave Medical Inc is a medical device company focused on developing and commercializing novel technologies that transform the care of patients with cardiovascular disease. It establishes a new standard of care for the treatment of calcified cardiovascular disease (“atherosclerosis”) through differentiated and proprietary local delivery of sonic pressure waves, which refer to as intravascular lithotripsy (“IVL”). Its IVL technology is a minimally invasive, easy-to-use, and safe way to improve outcomes for patients with calcified cardiovascular disease also IVL catheters enables delivery of IVL therapy to diseased vasculature throughout the body for calcium modification. |
URL | https://www.shockwavemedical.com |
Investor Relations URL | https://ir.shockwavemedical.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Aug. 05, 2024 |
Last Earnings Release | May. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Shockwave Medical Inc is a medical device company focused on developing and commercializing novel technologies that transform the care of patients with cardiovascular disease. It establishes a new standard of care for the treatment of calcified cardiovascular disease (“atherosclerosis”) through differentiated and proprietary local delivery of sonic pressure waves, which refer to as intravascular lithotripsy (“IVL”). Its IVL technology is a minimally invasive, easy-to-use, and safe way to improve outcomes for patients with calcified cardiovascular disease also IVL catheters enables delivery of IVL therapy to diseased vasculature throughout the body for calcium modification. |
URL | https://www.shockwavemedical.com |
Investor Relations URL | https://ir.shockwavemedical.com/ |
HQ State/Province | California |
Sector | |
Industry | |
Equity Style | Mid Cap/Growth |
Next Earnings Release | Aug. 05, 2024 |
Last Earnings Release | May. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |